Drug companies could save millions thanks to a new technology to monitor crystals as they form. The technique, developed by University of Leeds engineers, is a potentially invaluable tool in drug manufacture, where controlling crystal forms is crucial both to cost and product safety.
Most drug compounds are crystalline and their structure can affect both their physical attributes and their performance. Changes to these structures are often caused by undetected fluctuations in the process.
"If you were to use a pencil to write on glass you wouldn't get very far, but use a diamond and you could write your name. Yet both are pure forms of carbon. It's the same with different solid forms of the same drug; they can have completely different properties," says Dr Robert Hammond of the University's Faculty of Engineering, who leads the research team.
"Drug molecules are becoming increasingly complex and the challenges involved in processing them means that it is not always possible to successfully produce the desired form reliably. That's why there's such enormous potential for our system. We're now able to look at crystals as they are forming in a reactor, something that has never been done before."
The new technology identifies and monitors changes in crystal structures on-line, providing a method of ensuring production of the desired drug compounds. The bespoke system has been developed by engineers at the University of Leeds in collaboration with Bede X-Ray Metrology as part of the EPSRC funded Chemicals Behaving Badly programme.
Called polymorphism, changes in crystal structure during processing can lead to huge delays in bringing drugs to market, costing drug companies many millions of pounds. It can also lead to challenges to intellectual property protection. There have been a number of high profile cases where patents have been challenged by companies making an established formulation using a different polymorph.
"It's an enormous problem for drug companies," explains Dr Hammond. "Their patents are extremely valuable – they are granted for 20 years, but it can take ten years to bring a new drug to market, which only leaves another ten to recoup the cost of its development."
The technology developed at Leeds is based on the 'gold standard' method for monitoring crystal structures - powder X-ray diffraction, the primary tool for studying polymorphs.
"There's enormous commercial potential for this technology, for example it could be developed to work at manufacturing plant scales and can be applied to speciality chemical industries as well," says Dr Hammond. "We're interested in talking to pharmaceutical and speciality chemical companies that can help us drive this forward."
Source: University of Leeds
Related stories:
Researchers clarify function of glucose transport molecule
Researchers at the David Geffen School of Medicine at UCLA have solved the structure of a class of proteins known as sodium glucose co-transporters (SGLTs), which pump glucose into cells. These transport proteins are used in the treatment of chronic diarrhea via oral rehydration therapy, saving the lives of millions of children each year. The solution of the SGLT structure will accelerate development of new drugs designed to treat patients with diabetes and cancer.
NMR researchers unlock hydrogen’s secrets to spot polymorphism in pharmaceuticals
Researchers at the University of Warwick and Astra Zeneca have found a new way to use solid-state NMR equipment to crack the secrets of hydrogen atoms and thus spot unwanted polymorphs in pharmaceuticals.
Researchers clear way to stronger glass
Look at your window - not out it, but at it. Though the window glass looks clear, if you could peer inside the pane you would see a surprising molecular mess, with tiny particles jumbled together any which way.
Researchers test antibacterial effects of healing clays
Clay is most commonly associated with the sublime experience of the European spa where visitors have been masked, soaked and basted with this touted curative since the Romans ruled. If ASU geochemist Lynda Williams and microbiologist Shelley Haydel's research on the antibacterial properties of clays realizes its full potential, smectite clay could one day rise above cosmetic use to take its place comfortably with antibacterial behemoths like penicillin.
Researchers develop 'smart petri dish'
Researchers at the University of California, San Diego have developed what they call a "Smart Petri Dish" that could be used to rapidly screen new drugs for toxic interactions or identify cells in the early stages of cancer circulating through a patient's blood.
Researchers Find How Some Antibiotics Kill Bacteria
Researchers have uncovered how members of one family of antibiotics kill bacteria that make people sick.
Sharp Announces Second Generation 3D Notebook
Following a wake of awards and recognition for the Sharp Actius Notebook line, Sharp Systems of America today announced the availability of the Sharp Actius AL3D. Featuring Sharp’s 3D LCD Screen Technology, the Actius AL3D represents Sharp’s second generation of 3D Technology enhanced notebook systems.
Free drug samples may end up costing uninsured more
Free drug samples provided to physicians by pharmaceutical companies could actually be costing uninsured patients more in the long run, according to a study done by researchers at Wake Forest University Baptist Medical Center and colleagues.
